Lipid Disorder Treatment Market To Reach $51.53 Billion by 2035

Lipid disorder treatment market was valued at $30.60 billion in 2025 and is projected to reach $51.53 billion by 2035, growing at a CAGR of 5.35% during the forecast period (2026–2035). The rising global burden of cardiovascular diseases is a key macro driver supporting market growth. According to the World Health Organization (WHO), cardiovascular diseases account for nearly 17.9 million deaths annually, representing approximately 32% of all global deaths. Dyslipidemia is a major modifiable risk factor contributing to these conditions, leading to increasing demand for lipid-lowering therapies. Growing awareness regarding preventive healthcare, coupled with rising screening rates for cholesterol disorders, is further driving the adoption of treatment solutions across developed and emerging economies.

Browse the full report description of “Lipid Disorder Treatment Market Size, Share & Trends Analysis Report, By Drug Class (Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Fibrates, Omega-3 Fatty Acid-Based Therapies, Bile Acid Sequestrants, Combination Therapies, Emerging / Novel Therapies), By Disorder Type (Hypercholesterolemia, Hypertriglyceridemia, Mixed Dyslipidemia, Low HDL Cholesterol Disorders), By End User (Hospitals, Specialty Clinics / Cardiology Centers, Homecare / Self-administration), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/lipid-disorder-treatment-market

The increasing investment in pharmaceutical innovation and biologics is further strengthening the market outlook. According to the U.S. Food and Drug Administration (FDA), there has been a consistent rise in approvals of novel lipid-lowering drugs, including PCSK9 inhibitors and RNA-based therapies, which are transforming treatment paradigms. Additionally, data from the European Federation of Pharmaceutical Industries and Associations (EFPIA) highlights continuous R&D spending growth in cardiovascular therapeutics, supporting pipeline expansion. Hospitals remain the dominant end users due to access to specialized care and diagnostic infrastructure, while specialty clinics and homecare settings are gaining traction due to increasing preference for long-term disease management and self-administration therapies.

Rising Adoption of Advanced Lipid-Lowering Therapies Driving Market Growth

The drug class segment is witnessing strong growth due to increasing adoption of advanced therapies such as PCSK9 inhibitors and combination drugs. Statins continue to dominate due to their established efficacy and widespread prescription base. However, emerging therapies, including RNA-based drugs and novel biologics, are gaining momentum due to improved patient outcomes and reduced side effects. Hypercholesterolemia remains the leading disorder segment due to its high prevalence, while hypertriglyceridemia and mixed dyslipidemia are expected to witness steady growth. The end-user landscape is evolving with hospitals maintaining dominance, while specialty clinics and homecare settings are expanding due to increasing focus on personalized and long-term treatment approaches.

Key Leaders Transforming the Lipid Disorder Treatment Market

The key players in the lipid disorder treatment market include Amgen Inc., AstraZeneca PLC, Novartis AG, Sanofi S.A., Pfizer Inc., among others. These companies are focusing on product innovation, strategic collaborations, and expansion strategies to strengthen their market presence.

• In April 2026, Pfizer Inc. announced that it will present new oncology data at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026, scheduled from May 29 to June 2, 2026, in Chicago. The company will showcase data from more than 40 research abstracts, including late-breaking sessions and oral presentations, covering therapies such as LORBRENA, BRAFTOVI, TALZENNA, XTANDI, and TUKYSA. This development highlights Pfizer’s focus on strengthening its oncology pipeline through advanced clinical research and next-generation treatment combinations.
• In March 2026, Amgen Inc. announced that its PCSK9 inhibitor Repatha® (evolocumab) reduced the risk of first major adverse cardiovascular events by 31% in high-risk patients without known significant atherosclerosis, based on data from the Phase 3 VESALIUS-CV trial. The study demonstrated significant improvements in reducing heart attack, stroke, and cardiovascular death when used alongside standard lipid-lowering therapies. This development highlights the company’s focus on expanding the clinical utility of advanced biologic therapies and strengthening its position in the lipid disorder treatment market.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Drug Class
• Disorder Type
• End User
• Competitive Landscape – Amgen Inc., AstraZeneca PLC, Novartis AG, Sanofi S.A., Pfizer Inc., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Lipid Disorder Treatment Market Segmentation

By Drug Class

• Statins
• PCSK9 Inhibitors
• Cholesterol Absorption Inhibitors
• Fibrates
• Omega-3 Fatty Acid-Based Therapies
• Bile Acid Sequestrants
• Combination Therapies
• Emerging / Novel Therapies

By Disorder Type

• Hypercholesterolemia
• Hypertriglyceridemia
• Mixed Dyslipidemia
• Low HDL Cholesterol Disorders

By End User

• Hospitals
• Specialty Clinics / Cardiology Centers
• Homecare / Self-administration

Global Lipid Disorder Treatment Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/lipid-disorder-treatment-market